WHO: More than 100 reasons to quit tobacco.
More than 100 reasons to quit tobacco – World Health Organization Commentary on Twitter (thread – click for more) Quitting tobacco ? can be challenging but there are more than ? reasons to #CommitToQuit & start living a healthier life. Find out more ?https://t.co/8uBEMvH0cu pic.twitter.com/iwrt86xSVo — World Health Organization (WHO) (@WHO) June 13, 2021 […]
The post WHO: More than 100 reasons to quit tobacco. appeared first on Links Medicus.
Covid: Is there a limit to how much worse variants can get?
Covid: Is there a limit to how much worse variants can get? – BBC
The post Covid: Is there a limit to how much worse variants can get? appeared first on Links Medicus.
Video | Evaluation and care of patients with persistent symptoms following acute SARS-CoV-2 infection.
COVID-19: Evaluation and Care of Patients With Persistent Symptoms Following Acute SARS-CoV-2 Infection – Annals of Internal Medicine
The post Video | Evaluation and care of patients with persistent symptoms following acute SARS-CoV-2 infection. appeared first on Links Medicus.
RCT: No difference in 30-day mortality with discontinuation vs. continuation of renin-angiotensin-system inhibitors in patients with COVID-19, but secondary and explorative analysis showed discontinuation of RAS-inhibition may lead to a faster and better
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial – The Lancet Respiratory Medicine Editorial: RAS inhibition and COVID-19: more questions than answers? Related randomized trials showing no benefit from discontinuation: Randomized trial: No benefit from discontinuing ACE Inhibitors and ARBs in patients admitted with COVID-19 AND […]
The post RCT: No difference in 30-day mortality with discontinuation vs. continuation of renin-angiotensin-system inhibitors in patients with COVID-19, but secondary and explorative analysis showed discontinuation of RAS-inhibition may lead to a faster and better recovery. appeared first on Links Medicus.
Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pa
Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2 – JAMA Network Open Commentary: MIS-C Incidence 316 Persons Per 1 Million SARS-CoV-2 Infections – HealthDay Commentary on Twitter About 1 in every 3,000 children who got COVID ended up with MIS-C. MIS-C incidence among Black persons and Hispanic or Latino […]
The post Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons. appeared first on Links Medicus.
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – “no evidence of a difference between the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines”.
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – Nature Medicine Commentaries on Twitter The ChAdOx1 nCoV-19 and BNT162b2 #COVID19 #vaccines reduce incidence of new #SARSCoV2 infections by up to 65% with a single dose and up to 80% after two doses in the United Kingdom @kb_pouwels @ONS @Oxford_NDPH @UniofOxford https://t.co/K1f68MMYyO […]
The post Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – “no evidence of a difference between the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines”. appeared first on Links Medicus.
Lab study shows sera from persons fully vaccinated with the Pfizer–BioNTech vaccine can effectively neutralize B.1.617 (Delta) and other SARS-CoV-2 variants.
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants – Nature Commentary on Twitter An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 and B.1.525. https://t.co/7lXCVe7sPY — Carlos del Rio (@CarlosdelRio7) June 12, 2021
The post Lab study shows sera from persons fully vaccinated with the Pfizer–BioNTech vaccine can effectively neutralize B.1.617 (Delta) and other SARS-CoV-2 variants. appeared first on Links Medicus.
M-A: Safety of thoracentesis and tube thoracostomy in patients with uncorrected coagulopathy.
Safety of Thoracentesis and Tube Thoracostomy in Patients With Uncorrected Coagulopathy: A Systematic Review and Meta-analysis – CHEST Commentary: Is Thoracentesis Safe in Coagulopathic Patients? – JournalFeed
The post M-A: Safety of thoracentesis and tube thoracostomy in patients with uncorrected coagulopathy. appeared first on Links Medicus.
Opinion | The Covid-19 Delta variant poses a threat to our return to ‘normal’.
The Covid-19 Delta variant poses a threat to our return to ‘normal’ – CNN Commentary on Twitter In @CNNOpinion I offer thoughts on how the COVID Delta variant should cause the US to rethink national SARS-CoV-2 goal setting…as well as adjust other policy and communications strategies in response to the unique challenges posed by […]
The post Opinion | The Covid-19 Delta variant poses a threat to our return to ‘normal’. appeared first on Links Medicus.
Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection.
Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection – The Journal of Infectious Diseases
The post Naturally acquired SARS-CoV-2 immunity persists for up to 11 months following infection. appeared first on Links Medicus.